L Perey1, R Paridaens2, H Hawle1, K Zaman3, F Nolé4, H Wildiers2, M Fiche1, D Dietrich1, P Clément2, D Köberle1, A Goldhirsch4, B Thürlimann1. 1. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. 2. Department of General Medical Oncology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium. 3. Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Electronic address: Khalil.Zaman@chuv.ch. 4. Unit for Medical Care, Department of Medicine, European Institute of Oncology, Milan, Italy.
Abstract
BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: This is a phase II, open, multicenter, noncomparative study. Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease. Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days. RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B. CONCLUSIONS: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit with fulvestrant.
BACKGROUND: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment. PATIENTS AND METHODS: This is a phase II, open, multicenter, noncomparative study. Two patient groups were prospectively considered: group A (n=70) with AI-responsive disease and group B (n=20) with AI-resistant disease. Fulvestrant 250 mg was administered as intramuscular injection every 28 (+/-3) days. RESULTS: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined as objective response or stable disease [SD] for >or=24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was 3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B. CONCLUSIONS: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant, thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit with fulvestrant.
Authors: Rinath Jeselsohn; MacIntosh Cornwell; Matthew Pun; Gilles Buchwalter; Mai Nguyen; Clyde Bango; Ying Huang; Yanan Kuang; Cloud Paweletz; Xiaoyong Fu; Agostina Nardone; Carmine De Angelis; Simone Detre; Andrew Dodson; Hisham Mohammed; Jason S Carroll; Michaela Bowden; Prakash Rao; Henry W Long; Fugen Li; Mitchell Dowsett; Rachel Schiff; Myles Brown Journal: Proc Natl Acad Sci U S A Date: 2017-05-15 Impact factor: 11.205
Authors: Suzanne E Wardell; Matthew J Ellis; Holly M Alley; Koleen Eisele; Todd VanArsdale; Stephen G Dann; Kim T Arndt; Tina Primeau; Elizabeth Griffin; Jieya Shao; Robert Crowder; Jin-Ping Lai; John D Norris; Donald P McDonnell; Shunqiang Li Journal: Clin Cancer Res Date: 2015-05-19 Impact factor: 12.531
Authors: James D Joseph; Beatrice Darimont; Wei Zhou; Alfonso Arrazate; Amy Young; Ellen Ingalla; Kimberly Walter; Robert A Blake; Jim Nonomiya; Zhengyu Guan; Lorna Kategaya; Steven P Govek; Andiliy G Lai; Mehmet Kahraman; Dan Brigham; John Sensintaffar; Nhin Lu; Gang Shao; Jing Qian; Kate Grillot; Michael Moon; Rene Prudente; Eric Bischoff; Kyoung-Jin Lee; Celine Bonnefous; Karensa L Douglas; Jackaline D Julien; Johnny Y Nagasawa; Anna Aparicio; Josh Kaufman; Benjamin Haley; Jennifer M Giltnane; Ingrid E Wertz; Mark R Lackner; Michelle A Nannini; Deepak Sampath; Luis Schwarz; Henry Charles Manning; Mohammed Noor Tantawy; Carlos L Arteaga; Richard A Heyman; Peter J Rix; Lori Friedman; Nicholas D Smith; Ciara Metcalfe; Jeffrey H Hager Journal: Elife Date: 2016-07-13 Impact factor: 8.140
Authors: Harold J Burstein; Constance T Cirrincione; William T Barry; Helen K Chew; Sara M Tolaney; Diana E Lake; Cynthia Ma; Kimberly L Blackwell; Eric P Winer; Clifford A Hudis Journal: J Clin Oncol Date: 2014-10-27 Impact factor: 44.544